Glioblastoma drug developer files for $75M IPO

The Israeli biotech Vascular Biogenics has filed plans to raise $75 million in an IPO on Nasdaq. According to its F-1, the biotech is engaged in R&D work on new drugs to fight cancer and immune-inflammatory conditions. Its lead drug, VB-111, gained fast track status at the FDA for glioblastoma and is slated to begin Phase III in Q1 2015. Another drug, VB-201, "is an oral small molecule we are currently evaluating in Phase II clinical trials for psoriasis and for ulcerative colitis." The company plans to trade under the symbol "VLBX." F-1